In a statement from US Food and Drug Administration (FDA) commissioner, the organization said the coronavirus COVID-19 had caused drug shortages in the US supply chain. The FDA did not disclose the name of the drug or its manufacturer.
According to regulators, the manufacturer has warned the FDA that its location is directly affected by COVID-19, which affects the production of the active ingredient (API). The FDA has announced that an alternative to the drug exists and is working with manufacturers and others to correct the shortage.
You may look at the US FDA shortage list via https://wizmed.com/drug-shortages.
Although the number of drug shortages has decreased significantly in recent years, drug shortages place a significant burden on health care providers who may need to prescribe medications or prescribe alternative treatments.
The problem of drug shortages requires the attention and cooperation of all parties involved in delivering life-saving drugs to patients.
These include biopharmaceutical companies that make brand-name drugs, as well as generic and biosimilar manufacturers, wholesalers, distributors, pharmacies, and healthcare providers.
Biopharmaceutical companies are proactively working to prevent and reduce these problems in coordination with the U.S. Food and Drug Administration (FDA). and other stakeholders to address the root causes of drug shortages.
For healthcare providers and patients, the FDA provides up-to-date information on drugs that are reported to be in short supply or are being discontinued. Patients should discuss alternative treatment possibilities with their doctor if any medication is short.